Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Plus Therapeutics (PSTV) has appointed Dr. Michael Rosol as Chief Development Officer to lead the company's clinical, pre-clinical, and biomarker development activities. Dr. Rosol brings 25 years of experience in clinical trial design, operations, and regulatory execution to the company, which is preparing to move from mid-stage to pivotal trials next year.
Previously serving as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals, Dr. Rosol also worked at Novartis Pharmaceuticals leading biomarker development and translational imaging groups. His academic background includes a Ph.D. from Boston University focusing on biomedical and radionuclide imaging, and appointments at prestigious institutions including Harvard Medical School/Massachusetts General Hospital and Mayo Clinic.
Plus Therapeutics (PSTV) ha nominato Dr. Michael Rosol come Chief Development Officer per guidare le attività di sviluppo clinico, pre-clinico e di biomarcatori dell'azienda. Il Dr. Rosol porta con sé 25 anni di esperienza nella progettazione di studi clinici, nelle operazioni e nell'esecuzione normativa, mentre l'azienda si prepara a passare da studi di fase intermedia a studi pivotal il prossimo anno.
In precedenza, ha ricoperto il ruolo di Chief Medical Officer e Senior Vice President presso Navidea Biopharmaceuticals, e ha lavorato anche per Novartis Pharmaceuticals guidando lo sviluppo di biomarcatori e i gruppi di imaging traslazionale. Il suo background accademico include un dottorato di ricerca conseguito presso la Boston University, con un focus sull'imaging biomedico e sui radionuclidi, e incarichi presso istituzioni prestigiose come la Harvard Medical School/Massachusetts General Hospital e la Mayo Clinic.
Plus Therapeutics (PSTV) ha nombrado al Dr. Michael Rosol como Director de Desarrollo para liderar las actividades de desarrollo clínico, preclínico y de biomarcadores de la empresa. El Dr. Rosol aporta 25 años de experiencia en el diseño de ensayos clínicos, operaciones y ejecución regulatoria, mientras la empresa se prepara para pasar de ensayos de fase intermedia a ensayos pivotal el próximo año.
Anteriormente, se desempeñó como Director Médico y Vicepresidente Senior en Navidea Biopharmaceuticals, y también trabajó en Novartis Pharmaceuticals liderando el desarrollo de biomarcadores y grupos de imagenología traslacional. Su formación académica incluye un doctorado de la Boston University centrado en imagenología biomédica y radionúclidos, y nombramientos en instituciones prestigiosas como la Harvard Medical School/Massachusetts General Hospital y la Mayo Clinic.
플러스 테라퓨틱스 (PSTV)는 마이클 로솔 박사를 최고 개발 책임자로 임명하여 회사의 임상, 전임상 및 바이오마커 개발 활동을 이끌게 하였습니다. 로솔 박사는 임상 시험 설계, 운영 및 규제 실행 분야에서 25년의 경험을 가지고 있으며, 회사는 내년에 중간 단계에서 중요한 시험으로 전환할 준비를 하고 있습니다.
이전에는 나비디아 바이오제약에서 최고 의학 책임자 및 수석 부사장으로 재직했으며, 노바티스 제약에서도 바이오마커 개발 및 전이 이미징 그룹을 이끌었습니다. 그의 학문적 배경은 보스턴 대학교에서 생의학 및 방사성 동위원소 이미징을 전공하여 박사 학위를 취득하였으며, 하버드 의대/매사추세츠 종합병원 및 메이요 클리닉과 같은 저명한 기관에서의 경력이 포함되어 있습니다.
Plus Therapeutics (PSTV) a nommé Dr. Michael Rosol en tant que Directeur du Développement pour diriger les activités de développement clinique, préclinique et de biomarqueurs de l'entreprise. Le Dr. Rosol apporte 25 ans d'expérience dans la conception d'essais cliniques, les opérations et l'exécution réglementaire, alors que l'entreprise se prépare à passer d'essais de phase intermédiaire à des essais pivots l'année prochaine.
Auparavant, il a occupé le poste de Directeur Médical et Vice-Président Senior chez Navidea Biopharmaceuticals, et a également travaillé chez Novartis Pharmaceuticals en dirigeant le développement de biomarqueurs et des groupes d'imagerie translationnelle. Son parcours académique comprend un doctorat de la Boston University axé sur l'imagerie biomédicale et les radionucléides, ainsi que des postes dans des institutions prestigieuses telles que la Harvard Medical School/Massachusetts General Hospital et la Mayo Clinic.
Plus Therapeutics (PSTV) hat Dr. Michael Rosol zum Chief Development Officer ernannt, um die klinischen, präklinischen und Biomarker-Entwicklungsaktivitäten des Unternehmens zu leiten. Dr. Rosol bringt 25 Jahre Erfahrung in der Planung von klinischen Studien, im Betrieb und in der regulatorischen Umsetzung mit, während das Unternehmen sich darauf vorbereitet, im nächsten Jahr von der Mittelphase zu entscheidenden Studien überzugehen.
Vorher war er Chief Medical Officer und Senior Vice President bei Navidea Biopharmaceuticals und arbeitete auch bei Novartis Pharmaceuticals, wo er die Entwicklung von Biomarkern und die Gruppen zur translationalen Bildgebung leitete. Sein akademischer Hintergrund umfasst einen Doktortitel von der Boston University mit Schwerpunkt auf biomedizinischer und radionuklidischer Bildgebung sowie Positionen an renommierten Institutionen wie der Harvard Medical School/Massachusetts General Hospital und der Mayo Clinic.
- Strategic timing of appointment as company prepares to advance from mid-stage to pivotal trials
- New CDO brings 25 years of relevant experience in clinical trials and regulatory execution
- Dr. Rosol's expertise in radiotherapeutic drug development aligns with company's CNS cancer focus
- None.
AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company’s clinical, pre-clinical, and biomarker development activities.
"Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike’s background in oncology and radiotherapeutic drug development throughout the entire product lifecycle, along with his deep imaging and biomarker development background, is a perfect match for our clinical pipeline and stage of development."
Dr. Rosol has 25 years of experience in clinical trial design, operations, and regulatory execution. Most recently, he served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to his most recent role, Dr. Rosol worked at Novartis Pharmaceuticals, leading key biomarker development and translational imaging groups. Dr. Rosol’s Ph.D. from Boston University focused on biomedical and radionuclide imaging, and he has held various academic appointments at Harvard Medical School/Massachusetts General Hospital, Mayo Clinic, Children’s Hospital of Los Angeles/USC Medical School, and the Medical University of South Carolina.
"It’s an exciting time to join Plus Therapeutics in this unique role," said Michael Rosol, Ph.D., Plus Therapeutics Chief Development Officer. "The Plus pipeline and recently reported clinical data show real promise for patients with severe cancers of the CNS and my background and expertise strongly align with our clinical development plans and a path to FDA approval."
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3
About Glioblastoma (GBM)
GBM affects approximately 15,000 patients annually in the U.S. and is the most common and lethal form of brain cancer. The average life expectancy with GBM is less than 24 months, with a one-year survival rate of
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs, including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements under the heading Upcoming Events and Expected Milestones, and statements regarding the following: CLIA compliance certification of the Company’s Houston-based clinical laboratory; the potential promise of rhenium (186Re) obisbemeda; expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts;; development and utility of CNSide leptomeningeal metastases diagnostic test.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, including the ability of the Company to come into compliance with The Nasdaq Capital Market listing requirements; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
What is Dr. Michael Rosol's role at Plus Therapeutics (PSTV)?
When will Plus Therapeutics (PSTV) begin its pivotal trials?
What is Dr. Michael Rosol's previous experience before joining PSTV?
What type of cancer treatments is Plus Therapeutics (PSTV) developing?
